Ocugen (NASDAQ: OCGN) is one of 29 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it compare to its peers? We will compare Ocugen to similar businesses based on the strength of its analyst recommendations, dividends, earnings, valuation, risk, institutional ownership and profitability.
This is a breakdown of current ratings and price targets for Ocugen and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 10.30%. Given Ocugen’s peers higher probable upside, analysts clearly believe Ocugen has less favorable growth aspects than its peers.
Institutional & Insider Ownership
56.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 19.7% of Ocugen shares are held by insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Ocugen has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s peers have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.
This table compares Ocugen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Ocugen and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocugen Competitors||$1.39 billion||$142.47 million||17.54|
Ocugen’s peers have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.